JNJ Factor-Based Stock Analysis

Validea's guru fundamental report rates Johnson & Johnson (JNJ) at 88% using Partha Mohanram's P/B Growth Investor model, signaling significant interest for the large-cap Biotechnology & Drugs growth stock. This model identifies low book-to-market companies with characteristics for sustained future growth, and JNJ passed most fundamental criteria, though it notably failed the Research and Development to Assets test.

Analysis

Johnson & Johnson (JNJ) has been rated favorably by Validea's P/B Growth Investor model, achieving a score of 88%. This model, derived from Partha Mohanram's academic research, identifies low book-to-market growth stocks with fundamentals indicative of sustained future performance. The 88% score suggests a strong alignment with the strategy's criteria, surpassing the 80% threshold for interest. JNJ, a large-cap stock in the Biotechnology & Drugs sector, successfully passed eight distinct fundamental tests, including those for Book/Market Ratio, Return on Assets, Cash Flow from Operations to Assets, and stability metrics for sales and asset returns. However, the analysis flagged a notable failure in one specific area: the Research and Development to Assets ratio. For a company reliant on innovation, this particular metric suggests that, according to the model's parameters, its R&D investment level may be lagging relative to its asset base, a key point of consideration despite the otherwise strong quantitative profile.

Key Decisions for Investors

• Given the strong 88% score and positive marks on core fundamentals like Return on Assets and Cash Flow, investors following quantitative growth strategies may find this report supportive of a bullish stance on JNJ.
• The failure on the Research and Development to Assets metric warrants further due diligence; investors should scrutinize JNJ's R&D pipeline and spending relative to peers to assess if this signals a potential risk to long-term innovation and growth.
• This analysis should be treated as a single, quantitative signal; it is prudent to complement this model-driven view with qualitative analysis of JNJ's strategic initiatives, competitive landscape, and ongoing litigation risks before adjusting positions.